'Smart bomb' drug approved for late-stage beast cancer patients
Kadcyla can work up to 20 percent of all breast cancer sufferers
The "smart bomb" drug called Kadacyl could possibly help one fifth of sufferers in late-stage of the disease now that it has been approved by the Food and Drug Administration. The producers of Kadacyl, Genentech say the drug has added almost six months onto the lives of late-stage cancer sufferers in a clinical trial.
Kadacyl is a combination of the well-known drug Herceptin and a chemotherapy drug called DM1, which is too powerful to go straight into the bloodstream.
The drug has been proven effective on HER2-positive breast cancer, a protein which advances cancer growth, adding several months onto the life of many women who were facing death.
Human trials on 991 women with advanced stage HER2-positive breast cancer were found to have extended their lives by an average of 5.8 months compared to standard chemotherapy.
It's estimated that 20 percent of breast cancer sufferers suffer from HER2 protein breast cancer.
Breast cancer is the second most deadly type of cancer among American women. It's estimated that 232,340 women will be diagnosed with breast cancer and 39,620 will die as a result of the illness.
Genentech says the drug will be available in two weeks. NBC reports it is expensive at a cost of $94,000 for a 10 month course.
Genentech said it would help patients who couldn't afford to make the payments. "People who do not have health insurance, or who have reached the lifetime limit set by their insurance company, might qualify to receive Kadcyla free of charge," it said in the statement.
"Kadcyla is an antibody-drug conjugate representing a completely new way to treat HER2-positive metastatic breast cancer, and it helped people live nearly six months longer," Chief medical officer and Head of Global Product Development, Hal Barron, says.
"We currently have more than 25 antibody-drug conjugates in our pipeline and hope this promising approach will help us deliver more medicines to fight other cancers in the future."
© 2013, Distributed by NEWS CONSORTIUM.
- - -
Pope Benedict XVI's Prayer Intentions for January 2013
General Intention: The Faith of Christians. That in this Year of Faith Christians may deepen their knowledge of the mystery of Christ and witness joyfully to the gift of faith in him.
Missionary Intention: Middle Eastern Christians. That the Christian communities of the Middle East, often discriminated against, may receive from the Holy Spirit the strength of fidelity and perseverance.
Keywords: Kadcyla, breast cancer, FDA approval
Rate This Article
Leave a Comment
More Health News
- Is it really that simple? - Research suggests ordinary vitamin C kills drug-resistant TB
- HIV resurgent among Navajo tribe as deadly cases spike
- UK to give cancer patients genetic analysis just like Angelina Jolie
- Vitamin D found beneficial in treating asthma symptoms
- Study: Depressed women in 40s, 50s suffer more than twice for stroke risk
- Some experts say it's biologically possible to clone a human
- Study: Women live longer than men as their immune systems age more slowly
- Man declared dead for 40 minutes brought back to life with revolutionary machine
- IPad2 poses risks to those with pacemakers, 14-year-old girl discovers
- Fr. Paul Schenck: Finding Living Faith on Catechetical Sunday
- The Movie Yellow: Incest as 'Normal' and Cassavates's Slides Into the World of Woes
- The Chicago School Teachers Strike Reveals the Need For School Choice
- The Sexual Barbarians and the Dissolution of Culture
- The Happy Priest Challenges Us to Ask: Who is Jesus to Me?
- Michael Coren on Canadian Public Schools: Teachers, leave those kids alone
- We Cannot Ignore Our Consciences: Cardinal Dolan On Religious Liberty
- In the Face of Danger, Successor of Peter Travels to Lebanon as a Messenger of Peace
- Reflections on the Dignity and Vocation of Women: Who or What?